| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | UFI | Common Stock | Purchase | $123K | +5.5K | +0.37% | $22.43 | 1.51M | Dec 7, 2021 | Direct | F1 |
| transaction | UFI | Common Stock | Purchase | $138K | +6K | +0.4% | $23.03 | 1.52M | Dec 8, 2021 | Direct | F2 |
| transaction | UFI | Common Stock | Purchase | $257K | +11K | +0.72% | $23.40 | 1.53M | Dec 9, 2021 | Direct | F3 |
| holding | UFI | Common Stock | 30K | Dec 7, 2021 | By wife | F4 | |||||
| holding | UFI | Common Stock | 130K | Dec 7, 2021 | By Invemed Associates LLC | F5 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.02 to $22.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 to $23.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.06 to $23.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
| F4 | The reporting person disclaims beneficial ownership of these securities, and this Form 4 shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| F5 | The reporting person is the principal equity holder and President and CEO of Invemed Associates LLC. Pursuant to Instruction (4)(b)(iv) of Form 4, the reporting person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by such entity. The reporting person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his pecuniary interest therein and/or are not actually distributed to him. |